- conflicts or gaps
- [[{"field": {"value": "founders", "source_urls": ["https://www.ycombinator.com/companies/hepatx", "https://tracxn.com/d/companies/hepatx/__FT5Hf5R6X_OxVtYBvKfM2slMJ5JLEAqx5D2Wu4_Bj9Q", "https://www.thecompanycheck.com/company/b/hepatx/2gcywgfn89ucx46rk"]}, "issue": {"value": "Y Combinator lists only Eric Schuur as founder. Tracxn lists Pier Federico Gherardini, Eric Schuur, and Bruce R. Davis. Company Check lists Bruce R. Davis and Mark Chao as founders while also listing Eric Schuur as CEO/co-founder. Technology Networks (2018) describes Mark Chao as VP Clinical Development on founding team, not explicitly as co-founder.", "source_urls": ["https://www.ycombinator.com/companies/hepatx", "https://tracxn.com/d/companies/hepatx/__FT5Hf5R6X_OxVtYBvKfM2slMJ5JLEAqx5D2Wu4_Bj9Q", "https://www.thecompanycheck.com/company/b/hepatx/2gcywgfn89ucx46rk", "https://www.technologynetworks.com/cell-science/blog/developing-stem-cell-therapy-solutions-for-liver-disease-310255"]}}, {"field": {"value": "funding.total_raised_usd", "source_urls": ["https://tracxn.com/d/companies/hepatx/__FT5Hf5R6X_OxVtYBvKfM2slMJ5JLEAqx5D2Wu4_Bj9Q", "https://www.cbinsights.com/company/hepatx/financials", "https://bouncewatch.com/company/hepatx-corporation"]}, "issue": {"value": "Total funding inconsistent across databases: Tracxn $150K over 3 rounds; CB Insights $120K over 5 rounds; BounceWatch $250K over 4 rounds. Only NIH SBIR R43DK139879 ($175,964) confirmed in primary government record.", "source_urls": ["https://tracxn.com/d/companies/hepatx/__FT5Hf5R6X_OxVtYBvKfM2slMJ5JLEAqx5D2Wu4_Bj9Q", "https://www.cbinsights.com/company/hepatx/financials", "https://bouncewatch.com/company/hepatx-corporation", "https://www.highergov.com/grant/R43DK139879/"]}}, {"field": {"value": "funding.rounds", "source_urls": ["https://tracxn.com/d/companies/hepatx/__FT5Hf5R6X_OxVtYBvKfM2slMJ5JLEAqx5D2Wu4_Bj9Q", "https://www.cbinsights.com/company/hepatx/financials", "https://bouncewatch.com/company/hepatx-corporation"]}, "issue": {"value": "Round counts, dates, and amounts differ across Tracxn, CB Insights, and BounceWatch. No company press release or SEC filing consolidates equity rounds. CB Insights lists an unattributed VC round on 2024-04-12 with undisclosed amount.", "source_urls": ["https://tracxn.com/d/companies/hepatx/__FT5Hf5R6X_OxVtYBvKfM2slMJ5JLEAqx5D2Wu4_Bj9Q", "https://www.cbinsights.com/company/hepatx/financials", "https://bouncewatch.com/company/hepatx-corporation"]}}, {"field": {"value": "identity.display_name", "source_urls": ["https://www.ycombinator.com/companies/hepatx", "https://hepatx.com/", "https://www.cbinsights.com/company/hepatx"]}, "issue": {"value": "Branding varies: YC uses Hepatx; company site and press releases use HepaTx/HepaTx Corporation; CB Insights uses HepaTX.", "source_urls": ["https://www.ycombinator.com/companies/hepatx", "https://hepatx.com/", "https://www.biospace.com/press-releases/hepatx-corporation-awarded-nih-sbir-grant-to-advance-cell-therapy-monitoring-technology", "https://www.cbinsights.com/company/hepatx"]}}, {"field": {"value": "employees.snapshots", "source_urls": ["https://www.ycombinator.com/companies/hepatx", "https://hepatx.com/meet-the-team"]}, "issue": {"value": "YC team_size remains 4; no dated primary-source headcount update found. Company site shows two-person management team plus large advisory boards, which may not reflect full employee count.", "source_urls": ["https://www.ycombinator.com/companies/hepatx", "https://hepatx.com/meet-the-team"]}}, {"field": {"value": "products.Hx-001.development_stage", "source_urls": ["https://synapse.patsnap.com/drug/683bd64f45c94b9f8c1d5326b8459916", "https://newsnetwork.mayoclinic.org/discussion/a-mayo-clinic-collaboration-studies-engineered-stem-cells-for-liver-disease/"]}, "issue": {"value": "Synapse lists Hx-001 as preclinical with no active recruiting clinical trials. Mayo/HepaTx collaboration press and Mayo news describe path toward first-in-human safety studies but no registered clinical trial start date found in sources reviewed.", "source_urls": ["https://synapse.patsnap.com/drug/683bd64f45c94b9f8c1d5326b8459916", "https://newsnetwork.mayoclinic.org/discussion/a-mayo-clinic-collaboration-studies-engineered-stem-cells-for-liver-disease/", "https://www.prnewswire.com/news-releases/hepatx-enters-collaboration-with-mayo-clinic-to-advance-cell-therapy-technology-for-liver-disease-to-clinical-trials-302243375.html"]}}, {"field": {"value": "products.patents", "source_urls": ["https://synapse.patsnap.com/organization/ab2279d04129b1150b684da869e00b24", "https://hepatx.com/science"]}, "gap": {"value": "Company claims licensed Stanford IP and additional IP under development; Synapse assignee profile indexed in secondary database. Patent count and specific patent numbers not verified in primary patent office records in this research pass.", "source_urls": ["https://hepatx.com/science", "https://synapse.patsnap.com/organization/ab2279d04129b1150b684da869e00b24"]}}, {"field": {"value": "funding.investors", "source_urls": ["https://hepatx.com/", "https://www.cbinsights.com/company/hepatx/financials", "https://tracxn.com/d/companies/hepatx/__FT5Hf5R6X_OxVtYBvKfM2slMJ5JLEAqx5D2Wu4_Bj9Q"]}, "issue": {"value": "Investor lists differ by source. Company website highlights Y Combinator, StartX, Golden Seeds, Nahkoda VC, iSprout, and Bioverge as affiliations; CB Insights and Tracxn add Sand Hill Angels, Savantus Ventures, Argonautic Ventures, and iSelect Fund. StartX appears to be accelerator affiliation rather than confirmed equity investor.", "source_urls": ["https://hepatx.com/", "https://biobase.whitefordresearch.com/companies/hepatx", "https://www.cbinsights.com/company/hepatx/financials", "https://tracxn.com/d/companies/hepatx/__FT5Hf5R6X_OxVtYBvKfM2slMJ5JLEAqx5D2Wu4_Bj9Q"]}}, {"field": {"value": "exit_status.valuation_usd", "source_urls": ["https://www.cbinsights.com/company/hepatx/financials", "https://www.ycombinator.com/companies/hepatx"]}, "gap": {"value": "No public valuation, revenue, or audited financials found.", "source_urls": ["https://www.cbinsights.com/company/hepatx/financials", "https://www.ycombinator.com/companies/hepatx"]}}]]
- source urls
- ["https://biobase.whitefordresearch.com/companies/hepatx", "https://bouncewatch.com/company/hepatx-corporation", "https://hepatx.com/", "https://hepatx.com/meet-the-team", "https://hepatx.com/science", "https://newsnetwork.mayoclinic.org/discussion/a-mayo-clinic-collaboration-studies-engineered-stem-cells-for-liver-disease/", "https://synapse.patsnap.com/drug/683bd64f45c94b9f8c1d5326b8459916", "https://synapse.patsnap.com/organization/ab2279d04129b1150b684da869e00b24", "https://tracxn.com/d/companies/hepatx/__FT5Hf5R6X_OxVtYBvKfM2slMJ5JLEAqx5D2Wu4_Bj9Q", "https://www.biospace.com/press-releases/hepatx-corporation-awarded-nih-sbir-grant-to-advance-cell-therapy-monitoring-technology", "https://www.cbinsights.com/company/hepatx", "https://www.cbinsights.com/company/hepatx/financials", "https://www.highergov.com/grant/R43DK139879/", "https://www.prnewswire.com/news-releases/hepatx-enters-collaboration-with-mayo-clinic-to-advance-cell-therapy-technology-for-liver-disease-to-clinical-trials-302243375.html", "https://www.technologynetworks.com/cell-science/blog/developing-stem-cell-therapy-solutions-for-liver-disease-310255", "https://www.thecompanycheck.com/company/b/hepatx/2gcywgfn89ucx46rk", "https://www.ycombinator.com/companies/hepatx", "https://yc-oss.github.io/api/batches/summer-2018/hepatx.json"]